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Although the results of clinical trials support breast-conserving therapy as a replacement for mastectomy in early breast 
cancer, the question remains whether these results apply in routine clinical practice. In the present analysis the breast 
cancer-specific survival and recurrence-free survival of 464 consecutive patients with breast tumonrs _<3 cm across 
undergoing breast-conserving therapy were compared with a group of 459 patients with similar extent of disease and 
period of diagnosis undergoing mastectomy. All patients were treated in community hospitals in the south-eastern 
Netherlands. Median follow-up of both treatment groups was 6.2 years. After adjustment for the prognostic effects of 
age, tumour size, axUlary nodal status and adjuvant systemic therapy, neither breast cancer-specific survival nor 
recurrence-free survival differed significantly between the breast-conserving therapy group and the mastectomy group. 
This finding indicates that in routine clinical practice breast-conserving therapy may be as effective as mastectomy. 
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Introduction 
The efficacy of breast-conserving therapy (BCT) and 
mastectomy in early breast cancer has been compared in 
several randomized clinical trials carried out during the 
seventies and early eighties/-3 All trials yielded similar 
survival rates for the two types of primary treatment. At 
subsequent consensus meetings and in various national, 
regional and institutional guidelines for treatment, BCT has 
been considered an appropriate method of primary therapy 
for the majority of women with stage I or II breast cancer. 
Nonetheless, substantial variation still exists in the 
proportion of women receiving BCT between hospitals and 
across regions? 7 In addition, especially older women have 
been reported to be less likely to receive BCT. 6-~° This may 
reflect the current uncertainties about selection criteria and 
the effectiveness of BCT in routine clinical practice. 
In the south-eastern Netherlands, BCT was introduced 
into the treatment guidelines of the regional Breast Cancer 
Study Group in 1981. The area is exclusively served by 
community hospitals and one department of radiotherapy 
and characterized by a high and increasing incid6nce of 
early breast cancer) ~ Until 1991, the use of BCT increased 
gradually, although showing considerable variation between 
hospitals and being smaller in the elderly) 2 In a previous 
analysis of all patients treated with BCT between 1981 
and 1987, survival and recurrence rates appeared to be 
comparable to those reported in literature. ~3 In the current 
study we compared the breast cancer-specific survival and 
recurrence-free survival rate for BCT and mastectomy after 
a median follow-up of 6 years. 
Patients and methods 
Data were obtained from the population-based Eindhoven 
Cancer Registry, which serves a population of almost one 
million inhabitants in the south-eastern part of the 
Netherlands (7% of the Dutch population)? 4 Data were 
collected by the cancer registry from copies of the 
pathologist's reports and from the medical records of eight 
community hospitals and the regional department of 
radiotherapy. Between 1981 and 1987, 482 patients with an 
invasive breast umour -< 3 cm in diameter and post-surgical 
axillary nodal status No or Nt underwent BCT. During the 
same period 872 patients with breast cancer of the same 
stage had undergone modified radical mastectomy and from 
this group 500 patients were randomly selected: 150 from 
the period 1981-3 and 350 from the period 1984-7. 
At the departments of surgery and the department of 
radiotherapy all medical records were screened for clinical 
events, including the site and date of any recurrence (local, 
regional or distant) and the date of death, up to June 1992. 
Information on the vital status was obtained from general 
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Table 1. Characteristics ofpatients according to primary treatment 
Primary treatment 
Variable BCT Mastectomy 
(n = 464) (n = 457) 
Follow-up interval (years) 
Mean 6.2 6.2 
Range 0.8-1 I. I 0,4-11.2 
Age (years) 
<45 144 (31%) 79 (17%) 
46-65 251 (54%) 228 (50%) 
>_66 69 (15%) 150 (33%) 
Mean 51.6 58.3 
Range 27-85 26-87 
Period of primary treatment 
1981-3 127 (27%) 124 (27%) 
1984-7 337 (73%) 323 (73%) 
Tumour size (cm) 
<2.0 380 (82%) 259 (57%) 
2.1-3.0 84 (18%) 198 (43%) 
Nodal status 
pN0 346 (75%) 293 (64%) 
pNi I 18 (25%) 164 (36%) 
Adjuvant systemic therapy (Adj) 
according to nodal status 
pN0 without Adj 342 (99%) 288 (98%) 
pNo with Adj 4 (1%) 5 (2%) 
pNi without Adj 44 (37%) 85 (52%) 
pNo with Adj 74 (63%) 79 (48%) 
practitioners and municipal registries. Four patients 
undergoing mastectomy and one patient undergoing BCT 
could not be traced after the date of primary treatment. 
Another 39 and 17 patients were excluded from the 
mastectomy group and the BCT group respectively: 25 and 
10 with a previous breast umour, nine and six with another 
previous malignancy and five and one respectively with 
synchronous bilateral breast cancer. Ultimately 921 patients 
were available for analysis, 464 with BCT and 457 with 
modified radical mastectomy (Table 1). 
Guidelines for BCT and modified radical mastectomy 
were drawn up in 1981 by the regional Breast Cancer Study 
Group and adapted in 1983. Initially, all breast cancer 
patients with tumours < 2 cm across at mammography were 
considered candidates for BCT, but in 1984 3cm became 
the limit. Patients with relatively small breasts, diffuse 
microcalcifications on the mammogram, a tumour fixed to 
the muscles, or multiple breast umours were supposed to 
undergo mastectomy. From 1981 until 1987 the proportion 
of patients with a tumour <2cm who had BCT increased 
from 21% to 46%. The proportion of patients with tumours 
of 2-3cm having BCT increased from less than 10% to 
28%. 
According to the guidelines, breast-conserving surgery 
involved a wide local excision of the tumour with an 
attempted margin of at least l cm of healthy tissue. 
Mastectomy was supposed to be of the modified radical 
type, according to the method of Patey or Madden. Both 
types of surgery included axillary dissection. All patients 
who underwent breast-conserving surgery received total 
breast irradiation, usually 50Gy within 5 weeks with an 
additional booster dose of 14-15 Gy to the tumour bed. 
Of the mastectomy patients 52% underwent irradiation. 
Adjuvant systemic therapy was recommended only for 
axillary node-positive patients, regardless of the type of 
surgery. Chemotherapy (six cycles of cyclophosphamide, 
methotrexate and fluorouracil) was indicated for pre- 
menopausal patients and hormonal therapy (tamoxifen) for 
post-menopausal patients with oestrogen receptor-positive 
tumours. 
Breast cancer-specific survival and recurrence-free 
survival, calculated from the date of BCT or mastectomy, 
were used as endpoints in this study. Breast cancer-specific 
survival was based on death due to, or in the presence of, 
distant recurrence. Patients dying without distant recurrence 
and patients till living at the date of tile last follow-up 
were considered as censored. To determine recurrence-free 
survival each first recurrence (local, regional or distant) was 
scored as an event. Patients without umour ecurrence were 
considered withdrawn alive at the date of last follow-up 
or death. Local recurrence was defined as pathologically 
confirmed tumour growth in the preserved breast after BCT 
or in the chest wall after mastectomy, regional recurrence 
as pathologically confirmed tumour growth in lymph nodes 
in the ipsilateral axilla and/or infraclavicular fossa and/or 
parasternal lymph nodes; clinically confirmed relapse of 
breast cancer in any other location was considered as distant 
recurrence. 
The life-table method was used to perform the survival 
analysisJ 5To compare breast cancer-specific and recurrence- 
free survival in the BCT group and the mastectomy group 
the Cox proportional hazards model was used to adjust for 
the influence of the following prognostic factors: age, 
tumour size, axillary nodal status and adjuvant systemic 
therapyJ 6The resulting model parameters were converted 
to relative risks. 
Results 
The median follow-up time was 6.2 years for both treatment 
groups (Table 1). Between the BCT group and the 
mastectomy group there were significant differences in age, 
tumour size, and nodal status (Z2:P<0.001 ) (Table 1 ). Node- 
positive patients in the BCT group were more likely to 
receive adjuvant systemic therapy (Z2: P<0.001): 63% of the 
node-positive patients in the BCT group received any form 
of adjuvant systemic therapy vs 48% in the mastectomy 
group (Table 1). Of all node-negative patients only nine 
received adjuvant systemic therapy. 
A total of 198 patients died (21%), 84 after BCT and 114 
after mastectomy. Of all deaths 125 were breast cancer- 
related: 60 after BCT and 65 after mastectomy. At 7 years 
the breast cancer-specific survival rates were 84% (95% CI: 
80-88) for BCTpatients and 86% (95% CI: 82-90) for those 
treated with mastectomy (Fig. I). Adjuvant systemic therapy 
and nodal status were combined to one variable consisting 
of three categories when included into the multivariate Cox 
model. After adjustment for the potentially confounding 
effect of age, tumour size and the combined variable of 
nodal status and adjuvant systemic therapy, the relative risk 
for death due to breast cancer for the BCT group compared 
to the mastectomy group was 1.09 (P=0.67) (Table 2). 
Node-positive patients with adjuvant systemic therapy were 
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found to have a reduced relative risk of dying from breast 
cancer compared with node-positive patients without 
systemic therapy (RR=0.48; P=0.006) (Table 2). 
Tumour recurrence was detected in 104 BCT patients and 
in 119 mastectomy patients (Table 3). At 7 years, the 
actuarial recurrence-free survival rates were 77% (95% CI: 
73-81) for the BCT group and 71% (95% CI: 67-76) for 
the mastectomy group (Fig. 1). After adjustment for age, 
tumour size and the combined variable of nodal status and 
adjuvant systemic therapy, the relative risk for recurrence 
for the BCT group compared to the mastectomy group was 
0.96 (P=0.75) (Table 2). The recurrence risk was halved 
for node-positive patients who received adjuvant systemic 
therapy, compared to node-positive patients without 
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Fig. 1. Life table analysis. Breast cancer-specific survival (BC) 
and recurrence-free survival (RFS) after breast-conserving therapy 
(BCT) and mastectomy. ( - -=BC + BCT; - - I - -=BC + 
mastectomy; . . . .  RFS + BCT;--I-q--=RFS + mastectomy.) 
Tab le  2 .  Results of multivariate analysis of breast cancer-specific 
survival and recurrence-free survival (n = 921) 
Factor 
Breast cancer- Recurrence-free 
specific survival survival 
RR (95% RR (95% 
confidence limit) confidence limit) 
Primary treatment 
Mastectomy* 1 1 
BCT 1.09 (0.74--1.57) 0.96 (0.73-1.26) 
Age group (years) 
<45* I I 
46-65 0.77 (0.51-1.16) 0.83 (0.60--I.13) 
>66 0.77 (0.45-1.31) 0.64 (0.42-0.96) 
Tumour size (cm) 
<2.0* 1 I 
2.1-3.0 1.40 (0.94-2.06) 1.59 (1.19-2.10) 
Nodal status and 
adjuvant systemic 
therapy (Adj) 
pNI without Adj* 1 1 
pN, with Adj 0.48 (0.28-0.81) 0.50 (0.34-0.73) 
pN0t 0.29 (0.19-0.44) 0.34 (0.25-0.46) 
RR: Relative risk as compared to reference category. 
* Reference category; 1" including nine patients with adjuvant 
systemic therapy. 
Tab le  3. Site of first recurrence in both treatment groups 
Primary treatment 
BCT Mastectomy 
Type of first recurrence n (%) n (%) 
Local 27 (26) 15 (13) 
Regional 9 (9) 13 ( 11 ) 
Distant 63 (61) 85 (71) 
Local and regional 1 (1) 2 (2) 
Local and distant 1 (1) 1 (1) 
Regional and distant 3 (3) 3 (3) 
Total 104 (100) 119 (100) 
Twenty-seven recurrences occurred in the preserved breast 
in the BCT group, as the first site of failure, and 15 in the 
chest wall in the mastectomy group (Table 3). The actuarial 
local recurrence rates at 7 years were 7.6% (95% CI: 4.8-10.4) 
and 5.3% (95% CI: 2.9-7.7) respectively. Distant metastases 
developed in I0 of the 27 patients with local recurrence 
after BCT, and at the time of analysis ix of these had died 
with disseminated disease. Of the 15 patients with chest 
wall recurrence after mastectomy six developed istant 
metastases, of whom five died, four with and one without 
disseminated disease. 
Discuss ion  
Six major prospective randomized trials have now shown 
equivalent survival in comparisons of breast-conserving 
surgery and radiotherapy with mastectomyJ 7 22 Our study 
group was derived from community hospitals, and in 
contrast o most trial populations older patients were also 
included. The results indicate that the efficacy achieved in 
trial centres may be reproduced in routine clinical practice. 
We do not think that the non-random assignment of 
primary treatment has biased our results substantially. To 
prevent confounding by indication for primary treatment, 
the study was restricted to patients with a well-defined stage 
of early breast cancer. The possible confounding effects of 
age, tumour size, nodal status and adjuvant systemic therapy 
were eliminated in the multivariate analysis. The smaller 
proportion of node-positive patients with adjuvant systemic 
therapy in the mastectomy group is largely explained by 
the greater proportion of post-menopausal patients in this 
group and the regional guidelines concerning adjuvant 
systemic therapy. According to these guidelines post- 
menopausal patients with an oestrogen receptor-negative 
tumour were supposed not to receive tamoxifen. During 
the study period less than 10% of the post-menopausal 
patients with an oestrogen receptor-negative tumour 
received tamoxifen, whereas the proportion of node-positive 
women with oestrogen receptor-positive tumours increased 
from 50% to 80% between 1984 and 1987. u Currently, 
tamoxifen is given irrespective of the oestrogen receptor 
status of the tumour. 
Even after multivariate analysis the possibility remains 
of confounding by factors which have not been documented 
in the cancer egistry. Several relative contraindications for 
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the use of BCT, such as the presence of vascular invasion, 
extensive intraductal component or margin involvement, 
have not been taken into account, because information was 
not available at that time. However, these factors may have 
had only a slight effect on the results. First, patients were 
diagnosed before 1988, when knowledge of the 
pathophysiology of local recurrence and many of the risk 
factors for local recurrence after BCT was still limited. 
Second, most of the independent risk factors for relapse in 
the conserved breast are local features, which may not 
have any prognostic significance for breast cancer-specific 
survival. And in view of the low local recurrence rate after 
BCT in this study, local tumour characteristics ould only 
have exerted a small influence on recurrence-free survival. 
Though not the central aim of this analysis, we observed 
a significantly reduced risk of recurrence and death from 
breast cancer in node-positive patients receiving adjuvant 
systemic therapy. Such risk reductions are consistent with 
results from trials. -'3 Numbers were too small to perform a 
separate analysis of the expected impact of adjuvant systemic 
therapy on the local recurrence rate. 3'24-26 Another indirect 
finding was the better recurrence-free survival of patients 
> 66 years compared to patients <45 years. 
Though based on a non-randomized study, our findings 
indicate that BCT can be applied adequately in routine 
practice according to current standards. No significant 
differences were observed in the breast cancer-specific 
survival and recurrence-free survival between patients with 
early breast cancer who were selected for either BCT or 
mastectomy in the community hospitals in south-eastern 
Netherlands. 
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